Tatsuya Kawasaki

Dr. Tatsuya Kawasaki

orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2015 in Biomedicine & Pharmacotherapy
Verified
Journal Article
Closed access
TNTomohiro Nabekura
Tomohiro Nabekura
THTakashi Hiroi
Takashi Hiroi
TKTatsuya Kawasaki
Tatsuya Kawasaki
YUYuichi Uwai
Yuichi Uwai

7 February 2018 in ACS Omega
Verified
Journal Article
Open access
TNTomohiro Nabekura
Tomohiro Nabekura
TKTatsuya Kawasaki
Tatsuya Kawasaki
MFMichi Furuta
Michi Furuta
TKTomoji Kaneko
Tomoji Kaneko
YUYuichi Uwai
Yuichi Uwai
The drug efflux transporter P-glycoprotein, which is encoded by MDR1 (ABCB1), plays important roles in drug absorption, distribution, and elimination. We previously reported that dietary polyphenols such as quercetin, curcumin, honokiol, magnolol, caffeic acid phenetyl ester (CAPE), xanthohumol, and anacardic acid inhibit P-glycoprotein-mediated drug transport. In the present study, we investigated the effects of polyphenols on the expression of P-glycoprotein using human intestinal epithelial LS174T cells and a reporter plasmid expressing 10.2 kbp of the upstream regulatory region of MDR1. Honokiol, magnolol, CAPE, xanthohumol, and anacardic acid activated the MDR1 promoter in LS174T cells, and the cellular uptake of rhodamine 123 and calcein-AM, fluorescent substrates of P-glycoprotein, decreased in polyphenol-treated LS174T cells. These results suggest that dietary natural polyphenols can induce the drug efflux transporter P-glycoprotein and have the potential to promote food–drug interactions.

1 September 2014 in Pharmacological Research
Verified
Journal Article
Closed access
YUYuichi Uwai
Yuichi Uwai
RARyosuke Arima
Ryosuke Arima
CTChihiro Takatsu
Chihiro Takatsu
RFRyo Furuta
Ryo Furuta
TKTatsuya Kawasaki
Tatsuya Kawasaki
TNTomohiro Nabekura
Tomohiro Nabekura

1 June 2020 in Pharmaceutical Research
Verified
Journal Article
Closed access
PDF file
TKTatsuya Kawasaki
Tatsuya Kawasaki
YSYuichi Shiozaki
Yuichi Shiozaki
NNNaoki Nomura
Naoki Nomura
KKKumi Kawai
Kumi Kawai
YUYuichi Uwai
Yuichi Uwai
TNTomohiro Nabekura
Tomohiro Nabekura

1 March 2020 in Biochemistry and Biophysics Reports
Verified
Journal Article
Open access
TNTomohiro Nabekura
Tomohiro Nabekura
TKTatsuya Kawasaki
Tatsuya Kawasaki
MJMisuzu Jimura
Misuzu Jimura
KMKoichi Mizuno
Koichi Mizuno
YUYuichi Uwai
Yuichi Uwai
This study examined the effects of microtubule-targeting anticancer drugs (paclitaxel, cabazitaxel, and eribulin) on the expression of drug efflux transporter P-glycoprotein, which is encoded by MDR1. Paclitaxel and eribulin induced MDR1 promoter activity in a concentration-dependent manner, while cabazitaxel had little effect in human intestinal epithelial LS174T cells. Overexpression of the nuclear receptor pregnane X receptor (PXR) gene (NR1I2) enhanced paclitaxel- and eribulin-induced MDR1 activation, but expression of the nuclear receptor co-repressor silencing mediator for retinoid and thyroid receptors (SMRT) gene (NCOR2) repressed MDR1 activation. Eribulin increased the mRNA and protein expression of P-glycoprotein in LS174T cells. Cellular uptake of rhodamine 123 and calcein-acetoxymethyl ester (calcein-AM), P-glycoprotein substrates, decreased in paclitaxel- or eribulin-treated LS174T cells. Eribulin also increased MDR1 promoter activity in human breast cancer MCF7 cells. The results suggest that the microtubule-targeting anticancer drug eribulin can induce the drug efflux transporter P-glycoprotein via PXR in human intestinal and breast cancer cells and thus influence the efficacy of anticancer drugs.

12 June 2020 in Food & Function
Verified
Journal Article
Closed access
PDF file
TNTomohiro Nabekura
Tomohiro Nabekura
TKTatsuya Kawasaki
Tatsuya Kawasaki
YKYu Kato
Yu Kato
KKKazuyoshi Kawai
Kazuyoshi Kawai
SFSerena Fiorito
Serena Fiorito
YUYuichi Uwai
Yuichi Uwai
P-glycoprotein (encoded by MDR1) is a membrane transport protein expressed in the intestine, liver, kidney, placenta, and blood–brain barrier. It excludes various clinically important drugs from cells, such as verapamil, digoxin, tacrolimus, and vinblastine. Therefore, human P-glycoprotein plays important roles in drug absorption, distribution, and excretion. We reported previously that auraptene, a natural compound occurring widely in citrus fruit (e.g., grapefruit), inhibited P-glycoprotein-mediated drug transport. In this study, we investigated the effects of auraptene and other phenylpropanoids on P-glycoprotein expression using human intestinal epithelial LS174T cells and a reporter plasmid expressing 10.2 kbp of the upstream regulatory region of MDR1. Auraptene (7-geranyloxycoumarin), a prenylated coumarin, and several phenylpropanoids, such as 3-(4′-geranyloxy-3′-methoxyphenyl)-2-trans propenoic acid, derricidin [2′-hydroxy-4′-(prenyloxy)chalcone], and 3-(4′-geranyloxyphenyl)-propanoic acid, induced MDR1 promoter activity in LS174T cells. Overexpression of the nuclear receptor human pregnane X receptor gene (NR1I2) enhanced auraptene-induced MDR1 activation. Nuclear factor-kappaB inhibitors, Bay11-7082 and JSH-23, repressed MDR1 activation by auraptene. Western blot analyses showed the induction of P-glycoprotein expression in the auraptene-treated LS174T cells. The citrus phytochemical auraptene can induce the drug efflux transporter P-glycoprotein in human intestinal cells, and thus has the potential to cause food–drug interactions.